Phase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesity
The TOGETHER-PsA trial found that combining Zepbound with Taltz delivered a 31.7% rate of dual response (ACR50 + 10% weight loss) in patients with psoriatic arthritis and obesity, compared to 0.8% on Taltz alone. Two-thirds of PsA patients in the U.S. have obesity, making this combination relevant to a large population.
What This Means for You
The TOGETHER-PsA trial found that combining Zepbound with Taltz delivered a 31.7% rate of dual response (ACR50 + 10% weight loss) in patients with psoriatic arthritis and obesity, compared to 0.8% on Taltz alone. Two-thirds of PsA patients in the U.S. have obesity, making this combination relevant to a large population.
If you have psoriatic arthritis and you’re also carrying extra weight, you’ve been managing two conditions that make each other worse. Obesity increases joint inflammation. Joint pain makes it harder to exercise. It’s a cycle, and until now, treatment for one didn’t necessarily help the other. The TOGETHER-PsA trial tested whether treating both simultaneously with Zepbound (tirzepatide) and Taltz (ixekizumab) could break that cycle.
The results, presented at the AAD Annual Meeting and published in Arthritis & Rheumatology, were clear. Among patients receiving both medications, 31.7% achieved the dual endpoint of ACR50 (a 50% improvement in arthritis symptoms) plus at least 10% body weight loss. On Taltz alone, that number was 0.8%. Not a typo. Less than one percent. The combination also showed a 64% relative increase in ACR50 response compared to Taltz monotherapy, and improvements showed up as early as Week 4.
What makes this relevant to you: about two-thirds of psoriatic arthritis patients in the U.S. have obesity. That’s a huge overlap, and rheumatologists have known for years that weight loss improves PsA outcomes. But telling patients to “lose weight” while they’re in chronic pain isn’t a real treatment plan. This trial gives doctors actual data to support adding a GLP-1 medication to an existing biologic regimen. If you’re already on a biologic like Taltz for PsA and your weight is making your symptoms harder to control, this is a conversation to have with your rheumatologist.
The practical barrier, as always, is cost and access. Zepbound at self-pay runs $299 to $449/month through the KwikPen savings program. Insurance coverage for weight loss indications varies wildly. Providers like Found and Calibrate specialize in getting GLP-1 prescriptions covered, and they’re worth exploring if your insurance situation is complicated. Your rheumatologist can also help build a case for medical necessity when obesity is actively worsening your PsA.
Source: Eli Lilly Press Releases
Frequently asked questions
Can my rheumatologist prescribe Zepbound, or do I need a separate weight loss provider?
Any licensed prescriber can write a Zepbound prescription. Many rheumatologists are already familiar with GLP-1 medications because of the obesity-arthritis overlap. If your rheumatologist isn’t comfortable prescribing it, they can refer you to an obesity medicine specialist or you can use a telehealth provider like Calibrate or Found that coordinates with your existing care team. Bring the TOGETHER-PsA data to your appointment. It gives your doctor clinical evidence to support the combination.
Is this combination FDA-approved for psoriatic arthritis plus obesity?
Not yet as a labeled combination therapy. Zepbound is approved for weight management and Taltz is approved for PsA, plaque psoriasis, and ankylosing spondylitis. Doctors can prescribe both off-label based on clinical judgment, and the TOGETHER-PsA data supports doing so. Lilly may pursue a formal combination indication, but that would require additional regulatory submissions.
Will insurance cover Zepbound if I have PsA and obesity?
Coverage depends on your plan. Many insurers cover Zepbound for weight management if you meet BMI criteria (30+ or 27+ with a weight-related comorbidity). Having PsA alongside obesity strengthens the medical necessity argument. Your rheumatologist’s documentation of how weight affects your PsA control can help with prior authorization. If your commercial plan denies coverage, the Zepbound KwikPen self-pay option at $299 to $449/month through LillyDirect or retail pharmacies is an alternative.
Keep reading
Frequently Asked Questions
Can my rheumatologist prescribe Zepbound, or do I need a separate weight loss provider?
Is this combination FDA-approved for psoriatic arthritis plus obesity?
Will insurance cover Zepbound if I have PsA and obesity?
Original source
Read the full article at Eli Lilly Press Releases